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Abstract 16 
Prion diseases are caused by PrP
Sc
, a self-replicating pathologically misfolded protein that exerts 17 
toxicity predominantly in the brain. The administration of PrP
Sc
 causes a robust, reproducible and 18 
specific disease manifestation. Here we have applied a combination of translating ribosome affinity 19 
purification and ribosome profiling to identify biologically relevant prion-induced changes during 20 
disease progression in a cell-type specific and genome-wide manner. Terminally diseased mice with 21 
severe neurological symptoms showed extensive alterations in astrocytes and microglia. Surprisingly, 22 
we detected only minor changes in the translational profiles of neurons. Prion-induced alterations in 23 
glia overlapped with those identified in other neurodegenerative diseases, suggesting that similar 24 
events occur in a broad spectrum of pathologies. Our results suggest that aberrant translation within 25 
glia may suffice to cause severe neurological symptoms and may even be the primary driver of prion 26 
disease. 27 
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Introduction 29 
Prion diseases (PrD) are fatal neurodegenerative diseases that are caused by transmissible 30 
proteinaceous particles termed prions (Scheckel and Aguzzi, 2018). Prions consist primarily of PrP
Sc
, 31 
pathological aggregates of the cellular prion protein (PrP
C
) and can be highly infective. PrDs are 32 
conventionally classified as acquired, genetic and sporadic forms of the disease. While the cause of 33 
PrP
C
 aggregation differs, all PrDs show a similar disease progression characterized by a pronounced 34 
vacuolation phenotype, activation of microglia and astrocytes, and ultimately neuronal loss. Prions are 35 
most efficiently transmitted within one and the same animal species, yet PrDs have been described in 36 
numerous mammals and are remarkably similar. In particular, mouse models of PrD appear to 37 
recapitulate most aspects of the human disease including transcriptomic changes – a finding that sets 38 
them apart from other murine models of neurodegenerative disease (Burns et al., 2015). Importantly, 39 
PrDs share many hallmarks with other more common neurodegenerative diseases including 40 
Alzheimer’s and Parkinson’s disease, and genes linked to neurodegeneration in humans have been 41 
shown to be conspicuously downregulated in PrD mice (Burns et al., 2015). This suggests that 42 
lessons learned from the PrD mouse model may be relevant to our understanding as well as to the 43 
development of diagnostics and therapeutics in other neurodegenerative diseases.  44 
Several techniques have aimed at characterizing the molecular changes underlying 45 
neurodegeneration. One major hurdle when studying pathologies of the central nervous system 46 
(CNS) is selective vulnerability: the brain consists of many different cell types, yet most diseases only 47 
affect a subset of cells. The isolation of specific cell types followed by bulk sequencing (Zamanian et 48 
al., 2012) and single cell sequencing (Keren-Shaul et al., 2017) is often used to characterize CNS 49 
diseases and injuries, and has identified disease-associated signatures in different cell types. Yet 50 
single cell sequencing only allows for the assessment of highly-expressed genes. Moreover, all of 51 
these approaches require prolonged dissociation and cell sorting protocols, which can introduce 52 
artefacts. Alternatively, cell-type specific profiles can be generated from mice expressing tagged 53 
ribosomes in the cell type of interest via translating ribosome affinity purification (TRAP) followed by 54 
RNA sequencing (Heiman et al., 2014). RiboTag (RT) mice expressing HA tagged ribosomes in a Cre 55 
recombinase dependent manner (Sanz et al., 2009), have been used to profile multiple CNS cell 56 
populations without tissue manipulation procedures (Boisvert et al., 2018; Furlanis et al., 2019; 57 
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Haimon et al., 2018). The datasets generated from these experiments are likely to reflect the 58 
endogenous expression of mRNA very closely. 59 
Here, we have characterized cell type-specific molecular changes in PrD using a combination of 60 
TRAP and ribosome profiling. The select expression and isolation of tagged ribosomes, followed by 61 
the generation and sequencing of ribosome-protected fragments (RPFs) without any preanalytical 62 
manipulations enables the assessment of endogenous translation in a quantitative, genome-wide and 63 
cell-type specific manner. Profiling of control and PrD mice throughout disease progression revealed 64 
vast prion-induced translational changes in microglia and astrocytes, but surprisingly few changes in 65 
neurons. This suggests that the prion-induced molecular phenotypes reflect major glia alterations, 66 
whereas the behavioral phenotypes may be ascribed to just few neuronal changes or changes that 67 
were undetectable in our assay such as altered neuronal connectivity.  68 
  69 
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Results 70 
Generation of mice that express GFP-tagged ribosomes in PrD-relevant cells 71 
To characterize cell-type specific molecular changes during PrD progression in a genome-wide 72 
manner, we used a mouse strain that expresses a GFP-tagged version of a large ribosomal protein, 73 
RPL10a, in a Cre-dependent manner (Zhou et al., 2013). We bred this strain with several “Cre driver 74 
lines”, expressing Cre recombinase under the control of the Camk2a, Pvalb, Gfap or Cx3cr1 75 
promoters (Fuchs et al., 2007; Gregorian et al., 2009; Tsien et al., 1996; Yona et al., 2013), to induce 76 
the expression of GFP-tagged ribosomes in excitatory CamKIIa neurons, inhibitory parvalbumin (PV) 77 
neurons, astrocytes or microglia, respectively (Figure 1a). Double-transgene positive mice were 78 
intraperitoneally injected with RML6 prions or control brain homogenates and sacrificed at the 79 
indicated time points during disease progression (Figure 1a and Supplementary File 1). Brains or 80 
brain regions were dissected and immediately flash frozen in liquid nitrogen for cell-type specific 81 
ribosome profiling, or formalin-fixed and paraffin-embedded for immunohistochemical analyses. 82 
To confirm a cell-type specific expression of GFP-tagged ribosomes, we examined the brains of mice 83 
by immunofluorescence with anti-GFP antibodies. Neuronal CamKIIa and PV Cre drivers have 84 
previously been shown to specifically label the corresponding neuronal subpopulation. Consistently, 85 
the CamKIIa-driven GFP expression was detectable in all CamKIIa positive neurons in hippocampus 86 
and cortex (Figure 1b and Figure 1-figure supplement 1a) and PV-driven GFP expression was seen in 87 
all PV
+
 cells, most prominently in the cerebellum (Figure 1c and Figure 1-figure supplement 1b-c). Co-88 
staining with the neuronal marker NeuN, which is expressed in most neurons, confirmed that the 89 
CamKIIa promoter induced GFP expression in only a subset of NeuN
+
 neurons. In contrast, GFP-90 
expressing PV neurons were typically NeuN negative. These results show that neuronal GFP 91 
expression was limited to the cell type of interest in different brain regions. Importantly, the expression 92 
of GFP was strictly Cre-dependent (Figure 1b-c and Figure 1-figure supplement 1) indicating that the 93 
GFP:Rpl10a mouse strain does not exhibit leaky constitutive GFP expression. 94 
Glia-specific Cre drivers have proven more difficult to generate, and many of them show extensive 95 
neuronal expression. The mGFAP line 77.6 utilized in this study performs better than other astrocytic 96 
Cre drivers and expresses Cre almost exclusively in astrocytes (Gregorian et al., 2009). Indeed, we 97 
predominantly observed GFP expression in astrocytes (Figure 1d and Figure 1-figure supplement 1d) 98 




has been shown to display Cre-induced rearrangements not only in microglia but also in neurons, 100 
most likely due to Cx3cr1 promoter activity during neuronal development (Haimon et al., 2018). We 101 
therefore utilized an inducible Cx3cr1
CreER
 line and activated Cre expression in microglia by treating 102 
adult mice for four weeks with tamoxifen-containing chow. While these mice showed GFP expression 103 
in microglia and not in neurons (Figure 1e and Figure 1-figure supplement 1e), they have been 104 
reported to additionally express Cre in non-parenchymal macrophages (Goldmann et al., 2016), 105 
corresponding to roughly ~1% of Cre positive cells in Cx3cr1
CreER
 mice (Haimon et al., 2018). The 106 
expression of GFP in non-glia cell types, was taken into consideration in subsequent analyses. 107 
We further assessed expression changes of GFP and different cell markers between control and 108 
prion-injected brains at the terminal stage of PrD. Hallmarks of PrD include neuronal loss as well as 109 
pronounced micro- and astrogliosis. Consistently, glial GFP, IBA-1 (microglia marker) and GFAP 110 
(astrocyte marker) levels were markedly increased in terminal PrD brains. In contrast, we did not 111 
observe a clear difference in neuronal GFP, NeuN, CamKIIa or PV expression (Figure 1 and Figure 1-112 
figure supplement 1). This is consistent with previous observations from our lab, where no or only a 113 
minor decrease in neuronal cell number was evident at the terminal PrD stage in mice.  114 
 115 
Analysis of different CNS cells via cell-type specific ribosome profiling 116 
Typically, mice expressing tagged ribosomes are analyzed via immunoprecipitation and RNA 117 
sequencing to identify which transcripts are translated in a given cell (Heiman et al., 2014). In 118 
contrast, ribosome profiling yields an additional layer of information by determining the number of 119 
ribosome-protected fragments (RPFs). The number of RPFs is linked to the number of ribosomes per 120 
transcript and therefore to the translation rate. The combination of tagged ribosome 121 
immunoprecipitation and ribosome profiling thus allows the quantitative assessment of mRNA 122 
translation specifically in the cell types of interest. We therefore investigated mice expressing GFP-123 
tagged ribosomes in different PrD-relevant cells at multiple disease stages via cell-type specific 124 
ribosome profiling (all analyzed samples are detailed in Supplementary File 1). Briefly, RPFs were 125 
isolated via partial RNase digestion and GFP immunoprecipitation and subjected to library preparation 126 
and high-throughput sequencing (Figure 2a). Unique molecular identifiers (UMIs) were attached to 127 
each cDNA molecule to eliminate PCR duplicates, and only unique reads were included in all 128 
downstream analyses. To analyze PV neurons, microglia and astrocytes, we utilized one hemisphere 129 
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per library. Pooled cortices and hippocampi of one mouse were assessed to examine CamKIIa 130 
neurons. We additionally profiled cortex, hippocampus and hemispheres of Cre-negative mice, which 131 
did not express any GFP. We typically obtained 5-10 million unique reads per library (Figure 2-figure 132 
supplement 1a and Supplementary File 1), of which only a minority (≤ 10%) mapped to ribosomal 133 
RNA (Figure 2-figure supplement 1b and Supplementary File 1). Most aligned reads were coding 134 
sequence (CDS) reads (Figure 2b and Supplementary File 1), which is consistent with the ribosome 135 
occupancy of transcripts. Importantly, despite the increase in glia cells at the terminal stage, the 136 
libraries of all terminally diseased mice (green data points in Figure 2 and Figure 2-figure supplement 137 
1) were non-distinguishable from other libraries. One single library did not pass our quality criteria 138 
(>10
6
 unique reads and > 70% of CDS reads) and was excluded from downstream analyses 139 
(encircled in pink in Figure 2 and Figure 2-figure supplement 1). While representative Cre
+
 libraries 140 
showed a strong increase in RPF coverage at the translational start codon that tailed off, the excluded 141 
library showed a pattern that was more similar to Cre-negative libraries (Figure 2-figure supplement 142 
1c).  143 
We proceeded with summarized RPF counts per gene, referred to as RNA translation throughout the 144 
manuscript. Focusing initially on libraries generated from control mice at the earliest time point (~3 145 
months old mice), we visualized the relationship between the different libraries. A principal-component 146 
analysis (PCA) and hierarchical clustering based on Euclidean distances revealed a segregation of 147 
the different cell types as well as a similarity between the analyzed neuronal cell types (Figure 2c-d 148 
and Supplementary File 2). Cre-negative samples most likely recapitulate the average translation in 149 
the analyzed region. With astrocytes being a highly abundant cell type in the CNS (Miller, 2018), it 150 
was not surprising that Cre-negative samples were most similar to GFAP samples (Figure 2c). Cre-151 
negative samples were nonetheless clearly distinguishable from GFAP and other Cre
+
 samples 152 
(Figure 2d). 153 
 154 
Identification of preferentially translated transcripts in different cell types  155 
To confirm that we profiled the desired cell population, we compared our data with previously 156 
published studies. We defined the top 100 enriched genes in neurons (N), endothelial cells (EC), 157 
oligodendrocytes  (OL), astrocytes (AS) and microglia (MG) based on RNA sequencing data 158 
generated from these cell populations (Zhang et al., 2014). These cell types were purified from P7 159 
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mouse brains via cell dissociation, immunopanning and FACS, and were analyzed via RNAseq. In 160 
contrast, our datasets were generated via ribosome profiling of flash-frozen brain regions from 13-161 
week-old mice. Nonetheless, we observed that the top 100 enriched genes showed the highest 162 
translation in the corresponding RP dataset (Figure 3a and Supplementary File 3). We additionally 163 
assessed cell-type specific markers, defined by single-cell sequencing of the visual cortex from 2-164 
month-old mice (Hrvatin et al., 2018). As expected, marker genes for excitatory neurons, PV neurons, 165 
astrocytes and microglia showed the highest translation in the respective cell type (Figure 3-figure 166 
supplement 1 and Supplementary File 3). The comparison further revealed that we predominantly 167 
profiled subsets of excitatory neurons (L23, L5_1 and L5_3) and microglia (Micro_1). Additionally, 168 
macrophage markers were highly translated in the Cx3cr1 RP dataset, confirming previous 169 
observations that a minor fraction of Cx3cr1
CreER
 positive cells are non-parenchymal macrophages. 170 
Collectively, these results indicate that we indeed analyzed the desired cell population. 171 
We next identified genes that were differentially translated between the different cell types using 172 
DESeq2 (Figure 3-figure supplement 2 and Supplementary File 2). We defined preferentially 173 
translated genes (PTGs) in a specific cell type if they showed an absolute log2 fold change |log2FC| 174 
of more than 2 and an FDR of less than 0.05 in one cell type compared to the four other cell types. 175 
This yielded a total of 2692 PTGs, including 57 CamKIIa_CX, 50 CamKIIa_HC, 299 PV, 963 GFAP 176 
and 1323 Cx3Cr1 PTGs (Figure 3b). A heatmap displaying the translation of the 2692 PTGs shows a 177 
preferential translation of these genes in the respective cell type and that samples clustered according 178 
to cell type (Figure 3c).  179 
Several studies have previously assessed ribosome-associated RNAs in the same cell types (Boisvert 180 
et al., 2018; Furlanis et al., 2019; Haimon et al., 2018). Using the RiboTag (RT) mouse, which 181 
expresses HA-tagged ribosomes in a Cre-dependent manner the authors sequenced the 182 
immunoprecipitated RNA directly. In contrast, the combination of ribosome immunoprecipitation and 183 
ribosome profiling (RP) allowed us to assess cell-type specific translation in a quantitative manner. 184 
When comparing all RT and RP datasets with each other (Supplementary File 3) we observed the 185 
highest correlation between datasets that were generated from the same cell type (Figure 3d and 186 
colored comparisons in Figure 3-figure supplement 3a), and PTGs were most highly expressed in the 187 
corresponding cell type (Figure 3-figure supplement 3b). While RT and RP datasets of each cell type 188 
were overall highly correlated (Figure 3d), we also observed that a number of genes deviated from the 189 
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linear regression line, including several PTGs (colored in Figure 3d). On one hand this might reflect 190 
differences linked to the analyzed tissue or the library preparation, yet some are likely to correspond 191 
to genes that are characterized by a high or low translation rate. The deviation of RT and RP datasets 192 
was particularly evident for PV and Cx3cr1
+
 cells, which for PV can be at least partially ascribed to the 193 
analysis of different tissues (neocortex for RT vs a whole hemisphere for RP). In contrast, the same 194 
tissue (whole hemispheres) was analyzed to assess Cx3cr1
+
 cells via RT and RP, and, our RP 195 
dataset showed a higher correlation with an RNAseq dataset generated from sorted microglia than 196 
with the RT dataset from the same study. This indicates that the GFP immunoprecipitation followed by 197 
ribosome profiling might yield more specific results compared to HA immunoprecipitation followed by 198 
direct sequencing.  199 
 200 
Cell-type specific changes become only evident at late PrD stages  201 
To discover PrD-related molecular changes, we identified differentially translated genes (DTGs: 202 
|log2FC| > 1 and FDR < 0.05) in the previously mentioned cell types at different stages during disease 203 
progression (Figure 1a and Supplementary Files 4-8). Prion-induced changes only became evident at 204 
later disease time points, and except for few individual genes we could not detect any DTGs in any of 205 
the cell types at 2, 4, 8, and 16 weeks post prion inoculation (wpi). A PCA revealed a clear separation 206 
of control and PrD samples only at the terminal time point, most strikingly in GFAP and Cx3cr1
+
 cells 207 
(Figure 4-figure supplement 1). Consistently, we observed most prion-induced changes in GFAP
+
 and 208 
Cx3cr1
+
 cells at the terminal stage (Figure 4a and Figure 4-figure supplement 2; all significantly 209 
changing genes are colored in Figure 4-figure supplement 2; significantly changing genes with 210 
|log2FC| > 1 are summarized in Figure 4a). Both of these cell types already showed several 211 
translational changes at the pre-terminal stage, 24 wpi. Upon comparing prion-induced changes at the 212 




 cells and a high overlap 213 
between the changes at the two time points, especially among upregulated genes (Figure 4b-c). This 214 
indicates that the pronounced translational changes in astrocytes and microglia become evident 2 215 
months before the terminal stage, long before any PrD-related symptoms manifest. Both astrocyte 216 
activation and microglia proliferation are hallmarks of PrD, yet due to the nature of our assay, these 217 
changes reflect translational changes within the respective cell type and are not due to any 218 
differences in cell numbers.  219 
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Both glia cell types have been linked to numerous diseases and display characteristic transcriptional 220 
signatures in response to disease or other stimuli. Reactive A1 astrocytes are induced upon 221 
lipopolysaccharide treatment, microglia activation and ischemia, are characterized by the upregulation 222 
of complement cascade genes and are thought to contribute to neuronal death (Liddelow et al., 2017; 223 
Zamanian et al., 2012). Not surprisingly, we found A1 signature genes to increase with disease 224 
progression (Figure 4d and Supplementary File 7). We also observed an increase in A2 signature 225 
genes, corresponding to neurotrophic factors (Liddelow et al., 2017; Zamanian et al., 2012). The 226 
categorization of microglia into homeostatic and disease-associated (as well as other) microglia has 227 
largely replaced the initial categorization into pro-inflammatory M1 and anti-inflammatory M2 microglia 228 
(Dubbelaar et al., 2018). We have therefore opted for the more current categorization. Consistent with 229 
our observations for A1 genes, disease-associated microglia (DAM) genes increased during disease 230 
progression. In contrast, homeostatic microglia markers started to show a slight decrease at 24 wpi, 231 
that was more pronounced at the terminal stage of the disease (Figure 4e and Supplementary File 8). 232 
Similar observations have been reported for multiple neurodegenerative diseases (Keren-Shaul et al., 233 
2017), confirming that the appearance of DAMs and the concomitant loss of homeostatic microglia 234 
are hallmarks of multiple neurodegenerative diseases. 235 
Surprisingly, neuronal cell types displayed very few translational changes even at the terminal stage 236 
(Figure 4a), and we observed only a low correlation of prion-induced changes at the last two time 237 
points (Figure 4-figure supplement 3). This is particularly interesting as PrD is a neurodegenerative 238 
disease. As previously mentioned, our protocol does not allow us to assess the total number of 239 
analyzed cells, suggesting that the CamKIIa and PV neurons which are present in terminally diseased 240 
mice, show only minor translational changes, especially compared to astrocytes and microglia. 241 
Several of the genes that changed in neurons at 24 wpi were enriched in either astrocytes and/or 242 
microglia and these changes might reflect a glia contamination. Yet Sik1 (changing in CamKIIa 243 
cortical neurons) and Cyp2s1 and Oprm1 (both changing in PV neurons) were highest expressed in 244 
neurons, and it is possible that even such few changes are sufficient to induce neuronal dysfunction 245 
and symptoms.  246 
 247 
Different cell types display distinct PrD related changes  248 
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We next focused on the terminal disease stage. Hierarchical clustering based on Euclidean distances 249 
and a PCA revealed a segregation of the terminal samples according to both cell type and treatment 250 
(Figure 5a-b). We observed a low correlation between the translational changes in the different cell 251 
types (Figure 5-figure supplement 1a) and found that most prion-induced changes are cell-type 252 
specific (Figure 5c and Supplementary File 9). Yet five genes showed an increase in translation in all 253 
analyzed cell types: Gfap, Serpina3n, Apod, Mt1 and Lgals3bp (Figure 5-figure supplement 1b). All 254 
five genes are highly translated in astrocytes, microglia or both (Figure 5-figure supplement 1b and 255 
Supplementary File 9), indicating that the increase in neuronal translation of these common genes is 256 
likely a contamination and reflects the pronounced astro- and microgliosis at the terminal PrD stage. 257 
Interestingly, we detected pronounced regional differences in translation within one and the same cell 258 
type. The CamKIIa changes between cortex and hippocampus did not correlate (Figure 5d) and, apart 259 
from the common genes discussed above, only one additional gene was shared between the 260 
CamKIIa datasets. Similarly, most glia changes were specific to either astrocytes or microglia (Figure 261 
5e). Yet we also identified 170 genes that changed in both glia cell types, with most of them (n = 153) 262 
changing in the same direction. We analyzed the gene ontology (GO) terms associated with genes 263 
that increased specifically in astrocytes (n = 692), microglia (n = 442) or in both cell types (n = 136). 264 
We found an enrichment of immune response genes among all three groups of genes and, among 265 
astrocyte-specific increasing genes, an enrichment of terms related to cell adhesion and extracellular 266 
matrix organization, indicating that these processes might be affected in astrocytes (Figure 5f and 267 
Supplementary File 10). In contrast, many decreasing genes that are astrocyte-specific (n = 184) or 268 
shared (n = 17) have been linked to sterol and cholesterol biosynthesis, respectively, whereas 269 
microglia-specific decreasing genes (n = 640) were enriched for neuronal terms including synaptic 270 
transmission (Figure 5f and Supplementary File 10).  271 
As stated earlier, microglia proliferation and neuronal loss are hallmarks of PrD, complicating the 272 
interpretation of microglia-specific decreasing genes. To address if some microglia changes are an 273 
artefact, we compared the translational change in microglia to the translational enrichment in different 274 
cell types compared to microglia (Figure 5-figure supplement 1c). Indeed, we observed a negative 275 
correlation between the translational change in microglia and neuronal enrichment: many microglia-276 
specific decreasing genes (colored in blue) were strongly enriched in neuronal cell types (Figure 5-277 
figure supplement 1c: first three panels). We did not observe such a relationship for genes that were 278 
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enriched in astrocytes compared to microglia (Figure 5-figure supplement 1c: fourth panel) nor for 279 
genes that changed in astrocytes (Figure 5-figure supplement 1d). The decrease in neuronal-enriched 280 
genes specifically in microglia is thus likely an artefact and reflects a change in the composition of 281 
analyzed cell types, namely the increase in microglia relative to neurons. We believe that astrocyte-282 
enriched genes are less affected by an increase in microglia since astrocytes are a lot more abundant 283 
than specific neuronal subtypes. We therefore only consider microglia-specific decreasing genes that 284 
are enriched in neurons to be an artifact and have flagged these genes in Supplementary File 9.  285 
 286 
Cell-type specific ribosome profiling identifies novel PrD-induced changes  287 
We previously published an extensive database of RNA expression changes in the hippocampus 288 
upon intracerebral and intraperitoneal prion inoculation (Sorce et al., 2020), and intersected the 289 
intraperitoneal RNAseq datasets with the cell-type specific ribosome profiling data (Supplementary 290 
Files 9 and 11). While we did not observe a correlation between mRNA abundance and cell-type 291 
specific translational changes at 8wpi (Figure 6-figure supplement 1a), the datasets correlated at the 292 
terminal stage (Figure 6-figure supplement 1b), and many genes changed in both mRNA abundance 293 
and cell-type specific translation (Figure 6a).  294 
We previously reported that terminal mRNA abundance changes correspond to genes enriched in 295 
microglia and astrocytes. Consistently, we observed that microglia PTGs showed a strong increase in 296 
the RNAseq dataset (Figure 6b), and that more than a third of the genes changing in mRNA 297 
abundance are microglia PTGs (566 out of 1451), most of which specifically changed in the RNAseq 298 
dataset (Figure 6a, n = 411). The RNAseq dataset showed the highest correlation with GFAP 299 
translational changes (Figure 6c and Figure 6-figure supplement 1b), which is consistent with 300 
astrocytes being the most abundant cell type. Yet, many genes that increased in mRNA abundance 301 
were enriched in microglia (Figure 6d), and thus reflect microglia proliferation rather than an increase 302 
in microglia-gene expression on a cellular level. We specifically focused on four genes that were 303 
enriched in astrocytes (Glul and Gfap) and microglia (Aif1 encoding for IBA1, and Mmp9). While we 304 
observed no change in cell-type specific translation nor protein expression in whole brain extracts for 305 
Glul, the protein expression and the translation in all assessed cell types strongly increased for Gfap 306 
(Figure 6e-f and Figure 6-figure supplement 2a). This indicates that the number of astrocytes does not 307 
change during PrD, yet specific genes such as Gfap are strongly upregulated in astrocytes during PrD 308 
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progression. In contrast, we observed an increase in both IBA1 and MMP9 protein expression, 309 
whereas Aif1 translation did not change and Mmp9 translation even decreased, specifically in 310 
microglia (Figure 6e-f and Figure 6-figure supplement 2a). The increased microglia proliferation 311 
therefore not only accounts for the increase in IBA1 protein levels (no cell-type specific change in 312 
translation was detectable), but additionally masks the microglia-specific decrease in Mmp9 313 
translation. We additionally assessed NeuN expression in hippocampal and cortical lysates as well as 314 
PV expression in whole brain lysates but did not observe a decrease in neuronal markers in PrD 315 
(Figure 6g and Figure 6-figure supplement 2a). These results support our initial observation (Figure 1 316 
and Figure 1-figure supplement 1) that terminally diseased PrD mice showed no or only little neuronal 317 
loss and explain why neuronal enriched genes show no or only a minor decrease in the RNAseq 318 
dataset (Figure 6a).  319 
Since terminally sick PrD mice show an upregulation of GFAP and an increase in microglia, we 320 
determined the levels of Rpl10a:GFP in mice bred with GFAP Cre and Cx3cr1 Cre lines. promoters. 321 
GFP levels remained constant in GFAP Cre/Rpl10a:GFP mice (Figure 6-figure supplement 2b), 322 
indicating that an increased GFAP promoter activity does not lead to additional Cre recombination 323 
events. In contrast, GFP levels increased in Cx3cr1 Cre/Rpl10a:GFP mice (Figure 6-figure 324 
supplement 2c), most likely reflecting the increase in microglia numbers. These results are consistent 325 
with our ribosome profiling data and suggests that a difference in GFP expression does not impact 326 
our analyses. Collectively, our data highlights the importance of studying individual cell types, allowing 327 
us to identify ~1500 novel genes that showed PrD-dependent translational changes, which were 328 
missed with more conventional approaches such as RNAseq of brain regions. 329 
  330 
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Discussion 331 
Genome-wide prion-induced transcriptional changes were previously investigated in large brain 332 
regions through RNAseq (Kanata et al., 2019; Sorce et al., 2020). While these analyses can identify 333 
prominent changes in RNA expression, splicing and editing, they do not possess the resolution 334 
necessary to identify cell-type specific changes. Moreover, the assessment of entire brain regions 335 
cannot discriminate between RNA expression changes within one cell type and an altered cellular 336 
composition. A recent report described prion-induced molecular changes in neuronal-enriched 337 
microdissected regions in the hippocampus and cerebellum via microarrays and identified changes 338 
linked to neuronal function (Majer et al., 2019). Yet microdissection can fail to capture events 339 
occurring within neuronal processes or synapses and, crucially, may induce gene expression changes 340 
during the isolation procedure. Additionally, any differences in mRNA abundance do not necessarily 341 
translate into altered protein expression. In fact post-transcriptional regulation seems to be particularly 342 
important in the nervous system, and numerous RNA binding proteins are expressed in a neuron-343 
specific manner (Darnell, 2013), the dysregulation of mRNA translation has been linked to multiple 344 
neurodegenerative diseases (Kapur et al., 2017), and an activation of the unfolded protein response 345 
(UPR) in PrD mice has been shown to specifically affect the translation rather than the expression of 346 
RNAs (Moreno et al., 2012).  347 
Here we have addressed these limitations by investigating PrD-relevant cell types throughout disease 348 
progression. We have identified preferentially translated genes (PTGs) and prion-induced changes in 349 
the analyzed cell types. We assessed astrocytes and microglia due to their activation being 350 
characteristics of PrD, PV neurons because they have previously been shown to be severely affected 351 
in PrD (Ferrer et al., 1993; Guentchev et al., 1998), and CamKIIa positive pyramidal neurons in the 352 
cortex and hippocampus as major glutamatergic neuronal subtypes.  353 
Differently from single-cell sequencing, cell-type specific ribosome profiling assesses mRNA 354 
translation rather than expression, allows the identification of genome-wide changes and not only 355 
changes of highly expressed genes, and does not require manipulations likely to induce artefacts. 356 
One caveat of our approach lies within the unspecific pulldown of highly expressed genes, especially 357 
if they are expressed in an abundant cell type. Yet only five out of 2185 terminal changes changed in 358 
all five investigated cell types, indicating that the vast majority of changes are detectable in one or few 359 
cell types. In contrast, many neuronal-enriched genes appeared to decrease specifically in microglia. 360 
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The latter observation most likely reflects a contamination of neuronal genes combined with an 361 
altered cellular composition (fewer neurons compared to microglia are present at the terminal stage). 362 
Importantly, our data allows us to identify such situations and take them into account when 363 
interpreting quantitative data. Collectively, our approach enables the assessment of biologically 364 
relevant cell-type specific translation in a genome-wide manner, thereby complementing 365 
transcriptomic approaches. 366 
The murine PrD model assessed here did not show a major decrease in neurons at the terminal 367 
stage. While this observation is consistent with previous reports, they are in stark contrast to the 368 
pathological changes characteristic for human PrD patients. Compared to humans, whose lives can 369 
be somewhat prolonged due to medical interventions, mice must be euthanized at a relatively early 370 
endpoint, well ahead of terminal disease, in order to comply with animal-welfare regulations. While 371 
these rules may have some justification, they render it legally impossible to investigate the true 372 
endpoint of mouse prion models. Consequently, the difference in neuronal loss is likely to reflect a 373 
difference in the disease stage. Interestingly, we observed only minor translational changes in 374 
different neuronal populations, although terminal PrD mice displayed pronounced neurological 375 
symptoms including piloerection, hind limb clasping, kyphosis and ataxia. It is possible that even few 376 
translational changes in neurons suffice to induce neurological dysfunction and symptoms. 377 
Additionally, our approach did not allow us to assess the impact of non-translated RNAs. Alternatively, 378 
neurological changes are evoked by subtle differences affecting neuronal connectivity, which may be 379 
induced by the widespread glia alterations described above but may escape translational analyses.  380 
Translation of mRNA has previously been shown to be affected in a PrD mouse model which 381 
overexpresses PrP and are thus characterized by an accelerated PrD progression with pronounced 382 
loss of synapses and neurons (Moreno et al., 2012). These mice show a protracted UPR activation 383 
leading to increased phosphorylation of PERK and eIF2, a global decrease in translation (including 384 
of Actb, Snap25, and Psd95), as well as increased ATF4/CHOP expression and apoptosis. While it 385 
remains unclear in which cell types these changes occur, neuronal overexpression of GADD34 386 
globally decreased eIF2 phosphorylation in hippocampal extracts, rescued the reduced translation 387 
and neuronal loss, and increased survival. More recently, the same group could show that also 388 
astrocytic overexpression of GADD34 was neuroprotective and increased survival (Smith et al., 389 
2020), highlighting the importance of astrocytes in neurodegeneration. Interestingly, in our PrD mouse 390 
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model none of the analyzed cell types showed a differential translation of Actb, Snap25, Psd95 391 
(Dlg4), or Chop and only microglia showed an increased translation of Atf4. In addition, while Moreno 392 
et al. did not observe an increased expression of GADD34 in hippocampal extracts, we observed an 393 
increase in Gadd34 translation specifically in astrocytes, presumably leading to a reduced UPR. 394 
Considering the differences in UPR marker expression and neuronal loss between the different PrD 395 
mouse models, it is plausible that a reduced UPR activation in our mouse model might contribute to a 396 
less pronounced neurodegeneration.  397 
Previously identified glia signatures increased in our dataset, including disease associated microglia 398 
(DAM) genes as well as neurotoxic (A1) astrocyte genes. In contrast, homeostatic microglia genes 399 
decreased during PrD progression. Neurotoxic A1 astrocytes are induced by activated microglia and 400 
are highly abundant in several neurodegenerative diseases (Liddelow et al., 2017). Yet, while 401 
preventing A1 formation after acute CNS injury reduced the loss of axotomized neurons (Liddelow et 402 
al., 2017), A1-astrocyte ablation in prion-inoculated mice accelerated disease progression (Hartmann 403 
et al., 2019), indicates that A1 astrocytes in PrD could be neuroprotective. Combined with our 404 
observations that neurotrophic (A2) astrocyte genes and Gadd34 increase in astrocytes, these results 405 
suggest that astrocytes might play a central role in limiting prion toxicity.  406 





Animal experiments were performed in compliance with the Swiss Animal Protection Law, under the 411 
approval of the Veterinary office of the Canton Zurich (animal permits ZH040/15, ZH139/16). Mice 412 
were kept in a conventional hygienic grade facility, constantly monitored by a sentinel program aimed 413 
at screening the presence of all bacterial, parasitic, and viral pathogens listed in the Federation of 414 
European Laboratory Animal Associations (FELASA). The light/dark cycle consisted of 12/12 h with 415 
artificial light (40 Lux in the cage) from 07:00 to 19:00h. The temperature in the room was 21±1°C, 416 
with a relative humidity of 50±5%. The air pressure was controlled at 50 Pa, with 15 complete 417 
changes of filtered air per hour (HEPA H 14 filter; Vokes-Air, Uster, Switzerland). Up to five mice were 418 
housed in IVC type II long cages with autoclaved dust-free Lignocel SELECT Premium Hygiene 419 
Einstreu (140-160g/cage) (J. Rettenmaier & Söhne GmbH), autoclaved 20 x 21 cm paper tissues 420 
(Zellstoff), autoclaved hay and a carton refuge mouse hut as nesting material. Individual housing was 421 
avoided, and all efforts were made to prevent or minimize animal discomfort and suffering. Prion-422 
inoculated and control-injected mice were regularly monitored for the development of clinical signs 423 
and humane termination criteria were employed.  424 
The following mouse strains were used in this study: Rpl10a:GFP (RRID:IMSR_JAX:022367), 425 
Camk2a Cre (RRID:IMSR_JAX:005359), Cx3cr1
CreER
 (RRID:IMSR_JAX:021160), GFAP Cre 426 
(RRID:IMSR_JAX:024098), and Pvalb Cre (MGI: 3798581). To induce Cre recombinase expression, 427 
3-week old Cx3cr1
CreER
 mice received Tamoxifen chow (400mg/kg; TD.55125.I) for four weeks. 11-428 
week old mice were intraperitoneally injected with 100 μl of RML6 prions (passage 6 of Rocky 429 
Mountain Laboratory strain mouse-adapted scrapie prions) containing 8.02 log LD50 of infectious units 430 
per ml. Control inoculations were performed using 100 µl of non-infectious brain homogenate (NBH) 431 
from CD-1 mice at the same dilution. After inoculation, mice were initially monitored three times per 432 
week. After clinical onset, mice were monitored daily. Mice were sacrificed at pre-defined time points 433 
(corresponding to an age of 13 to 35 weeks) at the same time of the day. Prion-inoculated mice 434 
allocated to the terminal group were sacrificed upon clear signs of terminal PrD including piloerection, 435 
hind limb clasping, kyphosis and ataxia (corresponding to an age of 42 to 43 weeks). This time point 436 
corresponds to the last time point when mice can be humanely euthanized and is reached 31 - 32 437 
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weeks post intraperitoneal prion inoculation. Control-injected mice assigned to the latest time point 438 
group were sacrificed at the same time as terminally ill mice. 439 
Mice were sacrificed by carbon dioxide induced deep anesthesia followed by decapitation, and brains 440 
were immediately dissected. For ribosome profiling, brain regions (cortex and hippocampus) and 441 
hemispheres were dissected, and flash frozen in liquid nitrogen. For immunohistochemistry, whole 442 
brains were fixed overnight in formalin at 4˚C, and prion-decontaminated at RT (1h in 100% formic 443 
acid, followed by a post-fixation step of 2h in formalin) before being paraffin embedded. 444 
 445 
Immunohistochemistry 446 
Histological analyses were performed on 2-µm thick sections from formalin fixed, formic acid treated, 447 
paraffin embedded brain tissues. Sections were subjected to deparaffinization through graded 448 
alcohols, followed by heat-induced antigen retrieval performed in 10 mM citrate buffer (pH6). 449 
Stainings were performed with the following antibodies: IBA1 (1:125, Wako, 019-1974, 450 
RRID:AB_839504), GFAP (1:250, Dako, Z0334, RRID:AB_10013382), GFP (1:250, Rockland 451 
Immunochemicals, 600-101-215, RRID:AB_218182), NeuN (1:250, Merck Millipore, ABN78, 452 
RRID:AB_10807945), PV (1:500, Sigma Aldrich, P3088, RRID:AB_477329) and CamKlla (1:100, 453 
Santa Cruz Biotechnology, sc-5306, RRID:AB_626788). The following secondary antibodies were 454 
used: anti-goat Alexa 488 IgG (H+L) (1:1000, A11055, Invitrogen, RRID:AB_2534102), anti-mouse 455 
Alexa 555 IgG (H+L) (1:1000, A21422, Invitrogen, RRID:AB_2535844) and anti-rabbit Alexa 555 IgG 456 
(H+L) (1:1000, A31572, Invitrogen, RRID:AB_162543). Images were acquired using the Olympus 457 
BX61 Upright Fluorescence Microscope. 458 
 459 
Western blot analysis 460 
Samples were lysed in 1 ml cell-lysis buffer (20mM Hepes-KOH, pH 7.4, 150mM KCl, 5mM MgCl2, 461 
1% IGEPAL) supplemented with protease inhibitor cocktail (Roche 11873580001), homogenized at 462 
5000 rpm (15 sec) with a Precellys24 Sample Homogenizer (LABGENE Scientific SA, BER300P24), 463 
incubated on ice for 20 min and cleared by centrifugation at 20’000g, 4° C for 10 min in a tabletop 464 
centrifuge (Eppendorf 5417 R). Whole protein concentrations were measured with a BCA assay 465 
(Thermo Scientific). Samples were boiled in 4 x LDS (Invitrogen, supplemented with 10 mM DTT) at 466 
95°C for 10 min. 20 µg of total protein per sample were loaded on a gradient of 4-12% Novex Bis-Tris 467 
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Gel (Invitrogen) for electrophoresis at 80 V for 15 min, followed by constant voltage of 160 V. After 468 
transfer to PVDF or Nitrocellulose membranes with the iBlot system (Life Technologies), the 469 
membranes were blocked with 5% Sureblock (LubioScience) in PBS-T (PBS + 0.2 % Tween-20) for 470 
1h at room temperature. Primary antibodies were incubated overnight in PBS-T with 5 % Sureblock at 471 
4° C. The membranes were washed three times with PBS-T for 10 min before incubating with 472 
secondary antibodies coupled to horseradish peroxidase for 1 h at room temperature. Membranes 473 
were washed three times with PBS-T for 10 min and developed with a Crescendo chemiluminescence 474 
substrate system (Millipore). Signal was detected using a LAS-3000 Luminescent Image Analyzer 475 
(Fujifilm), and analyzed with Quantity One (Bio-Rad, RRID:SCR_014280). The same membranes 476 
were then reprobed by incubating them for 30 min at room temperature in Restore Western Blot 477 
Stripping Buffer (Thermo Fischer Scientific), followed by washing three times with PBS-T for 10 min 478 
and overnight incubation with the primary antibody anti-Calnexin (1:2000, Enzo Life Sciences, ADI-479 
SPA-865, RRID:AB_10618434) at 4° C. Secondary antibody incubation, development and detection 480 
were performed as described above. 481 
The following primary antibodies were used for Western Blot analysis: anti-IBA1 (1:1000, Wako, 019-482 
1974, RRID:AB_839504), anti-GFAP (1:1000, Dako, Z0334, RRID:AB_10013382), anti-GFP (1:1000, 483 
Rockland Immunochemicals, 600-101-215, RRID:AB_218182), anti-Calnexin (1:2000, Enzo Life 484 
Sciences, ADI-SPA-865, RRID:AB_10618434), anti-NeuN (1:2000, Merck Millipore, ABN78, 485 
RRID:AB_10807945), anti-MMP9 (1:1000, Abcam, ab38898, RRID:AB_776512), anti-Glutamine 486 
Synthetase (1:1000, Abcam, ab176562, RRID:AB_2868472) and anti-PV (1:500, Swant, PV27, 487 
RRID:AB_2631173). The following secondary antibodies were used: HRP tagged goat anti-rabbit IgG 488 
(H+L) (1:3000, 111.035.045, Jackson ImmunoResearch, RRID:AB_2337938) and HRP tagged 489 
donkey anti-goat IgG (H+L) (1:3000, Jackson ImmunoResearch, 705-035-147, RRID:AB_2313587). 490 
 491 
Ribosome profiling 492 
Samples were lysed at 5000 rpm (15 sec) with a Precellys24 Sample Homogenizer (LABGENE 493 
Scientific SA, BER300P24)  in 1ml lysis buffer (20mM Hepes-KOH, pH 7.4, 150mM KCl, 5mM MgCl2, 494 
1% IGEPAL, 0.5mM DTT, 40U/ml RNAsin Plus (Promega N2615), 100µg/ml cycloheximide, one 495 
Complete EDTA-Free Protease Inhibitor Cocktail tablet (Roche 11873580001) per 10ml). Lysates 496 
were incubated for 30 min on ice and centrifuged at 20’000g (10 min at 4˚C) before being subjected to 497 
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partial RNA digestion via 45 min incubation at RT with CaCl2 (1mM final) and 300U micrococcal 498 
nuclease (0.3U/ml; Thermo Scientific EN0181). The reaction was stopped by placing samples on ice 499 
and adding EGTA (10mM final). GFP-tagged ribosomes were immunoprecipitated with a 1:1 mixture 500 
of monoclonal GFP antibodies (Memorial Sloan Kettering Monoclonal Antibody Facility, 19F7 and 501 
19C8, RRID:AB_2716736 and RRID:AB_2716737). 200µl protein G beads (Invitrogen 10004D), were 502 
coupled with 25µg of each antibody, incubated with brain lysates for 1h at 4˚C and washed three 503 
times with wash buffer (50mM Tris, pH7.5, 500mM KCl, 5mM MgCl2, 1% IGEPAL, 0.5mM DTT, 504 
40U/ml RNAsin Plus, 100µg/ml cycloheximide). RPFs were isolated by incubating beads for 15 min in 505 
release buffer (20mM Hepes-KOH, pH 7.4, 100mM NaCl, 30mM EDTA, 0.5mM DTT, 40U/ml RNAsin 506 
Plus), addition of NaCl (0.5M final) and 10 min incubation, and ultracentrifugation at 200’000g (2h at 507 
4˚C). The RPF-containing supernatant was run over G25 columns (GE Healthcare 95017-621) and 508 
incubated with 4U alkaline phosphatase (Roche 10713023001) to remove 3’ phosphates. RPFs were 509 
extracted with Trizol LS (Invitrogen 10296-028) according to the manufacturer’s recommendations 510 
and subjected to ligation (2h at RT) with a pre-adenylated 3’ linker (2µM final) and a truncated T4 511 
ligase (NEB M0373L). Ligated RPFs of 50 – 70 nucleotides (nt) were size selected by Urea PAGE 512 
electrophoresis and eluted by incubating crushed gel pieces at 1’200rpm (45 min at 50˚C) with 1M 513 
NaOAc (pH 5.2) and 1mM EDTA. Gel pieces were removed with filter tubes (Corning 8160), and RNA 514 
was precipitated before being reverse transcribed with SSIII (Invitrogen 18080-044) in the presence of 515 
BrdUTP (Sigma B0631, RRID:AB_306886). RT primers and the cloning and isolation of BrdUTP-516 
labeled footprints have previously been described (Hwang et al., 2016; Weyn-Vanhentenryck et al., 517 
2014). Briefly, the RT primer contains a 14-nt degenerate linker (a 3-nt degenerate sequence, a 4-nt 518 
multiplexing index, and a 7-nt unique molecular identifier), a 5’linker for PCR amplification, a spacer to 519 
prevent rolling circle amplification after circularization, and the reverse-complementary sequence of 520 
the 3’linker for reverse transcription. BrdUTP-labeled cDNA was specifically isolated via two 521 
sequential BrdUTP immunoprecipitations (with Abcam AB8955) and circularized with CircLigase II 522 
(Epicentre CL9025K). RPF libraries were PCR amplified with Phusion High-Fidelity DNA Polymerase 523 
(NEB M0530A) and the primer set DP5-PE/SP3-PE. The addition of SYBR Green (Invitrogen S7563) 524 
to the PCR reaction allowed us to track and stop library amplifications as soon as sufficient DNA had 525 
been generated to prevent overamplification-related PCR artifacts. Ribosome profiling libraries were 526 
isolated with AMPure XP beads (Agencourt A63880), quantified using the QIAxcel DNA High 527 
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Resolution Kit for pooling. The quality and quantity of the pooled libraries were validated using 528 
Tapestation (Agilent, Waldbronn, Germany). The libraries were diluted to 10nM in 10mM Tris-Cl, pH 529 
8.5 containing 0.1% Tween 20. The TruSeq SR Cluster Kit v4-cBot-HS (Illumina, Inc, California, USA) 530 
was used for cluster generation and sequencing was performed on a Illumina HiSeq 2500 single end 531 
50 bp using the TruSeq SBS Kit v4-HS (Illumina, Inc, California, USA). 532 
 533 
Primer sequences 534 
Pre-adenylated 3’ linker  535 
5rApp/GTGTCAGTCACTTCCAGCGG/3ddC 536 
RT primer #1: 537 
/5Phos/DDDCGATNNNNNNNAGATCGGAAGAGCGTCGT/iSp18/CACTCA/iSp18/CCGCTGGAAGT538 
GACTGAC 539 
RT primer #2: 540 
/5Phos/DDDTAGCNNNNNNNAGATCGGAAGAGCGTCGT/iSp18/CACTCA/iSp18/CCGCTGGAAGT541 
GACTGAC   542 
RT primer #3:  543 
/5Phos/DDDATCGNNNNNNNAGATCGGAAGAGCGTCGT/iSp18/CACTCA/iSp18/CCGCTGGAAGT544 
GACTGAC 545 
RT primer #4: 546 
/5Phos/DDDGCTANNNNNNNAGATCGGAAGAGCGTCGT/iSp18/CACTCA/iSp18/CCGCTGGAAGT547 
GACTGAC 548 
RT primer #5: 549 
/5Phos/DDDCTAGNNNNNNNAGATCGGAAGAGCGTCGT/iSp18/CACTCA/iSp18/CCGCTGGAAGT550 
GACTGAC 551 
RT primer #6: 552 
/5Phos/DDDGATCNNNNNNNAGATCGGAAGAGCGTCGT/iSp18/CACTCA/iSp18/CCGCTGGAAGT553 
GACTGAC 554 












Data analysis 566 
Ribosome profiling reads were processed with CTK (RRID:SCR_019034; Shah et al., 2017) and the 567 
FASTX-Toolkit (RRID:SCR_019035). Fastq files were de-multiplexed based on the 4-nt multiplexing 568 
index and filtered based on quality score (minimum of 20 from nt 1-14, mean of 20 from nt 15-40). 569 
The 3’linker was removed, exact sequences were collapsed, and the 14-nt adaptor was trimmed. 570 
Reads were aligned to the GRCm38.p5 build of the mouse genome and uniquely aligned reads were 571 
summarized per gene using STAR v2.6.0c (RRID:SCR_015899; Dobin et al., 2013). STAR gene 572 
count output files were analyzed in R (www.r-project.org, RRID:SCR_001905; Ihaka and Gentleman, 573 
1996), using Bioconductor (RRID:SCR_006442; Gentleman et al., 2004), and the packages “DESeq2” 574 
(RRID:SCR_015687; Love et al., 2014) and “ggplot2” (RRID:SCR_014601; Wickham, 2016). Data 575 
discussed in this manuscript has been deposited in the GEO database and is accessible through 576 
accession number GSE149805. 577 
Gene Ontology analyses were performed with GORILLA (RRID:SCR_006848; http://cbl-578 
gorilla.cs.technion.ac.il). We compared genes specifically decreasing (164 out of 184 were present in 579 
the GO database) or increasing (634 out of 692 were present) in astrocytes to astrocyte-expressed 580 
genes (12,888 out of 14,280 were present). Genes specifically decreasing (600 out of 640 were 581 
present in the GO database) or increasing (422 out of 442 were present) in microglia were compared 582 
to microglia-expressed genes (11,164 out of 11,919 were present), and genes decreasing (13 out of 583 
17 were present) or increasing (126 out of 136 were present) in both astrocytes and microglia were 584 
compared to genes expressed in both cell types (13,329 out of 14,837 were present). 585 
  586 
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Figure Legends 595 
 596 
Figure 1: Generation of mice that express GFP-tagged ribosomes in prion disease relevant 597 
cells. a, Schematic displaying which cell types were analyzed at which time point during prion 598 
disease (PrD) progression. b, Brain sections of control (ctrl) and terminally PrD CamKIIa/Rpl10a:GFP 599 
mice were stained for GFP and CamKIIa or NeuN. A subset of NeuN
+
 cells and all CamKIIa
+
 cells 600 
showed Rpl10a:GFP expression in the hippocampus. No GFP signal was detectable in Rpl10a:GFP 601 
mice (not bred with a Cre expressing strain). c, Brain sections of ctrl and PrD PV/Rpl10a:GFP mice 602 
were stained for GFP and PV or NeuN. Cells that were NeuN-negative and PV
+
 showed Rpl10a:GFP 603 
expression in the cerebellum. No GFP signal was detectable in Rpl10a:GFP mice (not bred with a Cre 604 
expressing strain). d, Brain sections of ctrl and PrD mice expressing Rpl10a:GFP in GFAP
+
 cells were 605 
stained for GFP and GFAP. e, Brain sections of terminally diseased and control mice expressing 606 
Rpl10a:GFP in Cx3cr1
+
 cells were stained for GFP and IBA1.  607 
 608 
Figure 2: Analysis of different CNS cells via cell-type specific ribosome profiling. a, Schematic 609 
depicting the workflow of cell-type specific ribosome profiling. After partial RNase digestion, GFP 610 
ribosome protected fragments (RPF) were isolated via GFP immunoprecipitation and 611 
ultracentrifugation, and subjected to 3’ linker ligation, reverse transcription, circularization and PCR 612 
amplification before being submitted for high-throughput sequencing. b, Beeswarm plots displaying 613 
the % of reads mapping to the coding sequence (CDS). Samples are grouped according to analyzed 614 
regions and Cre drivers. Only Cre
+
 samples with a minimum of 70% CDS reads (indicated by a 615 
dashed pink line) were analyzed. One Cre
+
 sample did not pass quality control and was therefore 616 
excluded (encircled in pink). Terminal PrD samples are colored in green. c, Principal component 617 
analysis of noCre samples and control samples at 2 weeks post inoculation (wpi) based on rlog 618 
transformed RPF counts per gene revealing a separation according to Cre driver (~ cell type), a 619 
resemblance of GFAP samples and noCre samples and similarities between neuronal cell types. d, 620 
Hierarchical clustering of noCre samples and control samples at 2 wpi based on Euclidean distances. 621 
Heatmaps depicting the sample distance at each time point based on rlog transformed RPF counts 622 
per gene. Samples cluster according to Cre driver (~ cell type) and noCre samples are clearly 623 
distinguishable.  624 
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 625 
Figure 3: Identification of preferentially translated transcripts in different cell types. a, Boxplots 626 
displaying the translation (log2 transformed fpkm values) of the top 100 genes in neurons (N), 627 
endothelial cells (EC), oligodendrocytes (OL), astrocytes (AS) and microglia (MG) in the indicated cell 628 
type. Boxes containing genes expected to be highly translated are shaded in a darker tone. b, 629 
Identification of genes that were differentially translated (|log2FC| > 2 and FDR < 0.05) between two 630 
different cell types (numbers on lines) and of preferentially translated genes (PTGs) that were 631 
differentially translated in one versus all other cell types (numbers in colored hexagons). c, Heatmap 632 
displaying the translation (log2 transformed fpkm values) of 2692 PTGs, revealing a clustering of 633 
samples according to cell type. d, Scatterplots comparing the translation (log2 transformed fpkm 634 
values) and the expression (assessed via ribosome immunoprecipitation followed by sequencing; log2 635 
transformed fpkm values) in the indicated cell type. Translation and expression of CamKIIa and 636 
Cx3cr1 positive cells were assessed in corresponding brain regions. In contrast, PV and GFAP 637 
translation was examined in the whole brain, whereas PV expression was analyzed in neocortex and 638 
GFAP expression corresponds to the averaged expression across multiple regions 639 
(motor/somatosensory/visual cortex, cerebellum and hypothalamus). Linear regression lines are 640 
indicated and PTGs in the respective cell types are colored.   641 
 642 
Figure 4: Cell-type specific changes become only evident at late prion disease stages. a, 643 
Schematic depicting numbers of differentially translated genes (DTGs: |log2FC| > 1 and FDR < 0.05) 644 
in the indicated cell types at different stages during disease progression (in the corresponding Figure 645 
4-figure supplement 2 all genes with an FDR < 0.05 are colored, independent of their log2FC). b, 646 
Scatterplot comparing prion-induced changes in GFAP
+
 cells at the pre-terminal (24 weeks post 647 
inoculation (wpi)) and terminal time points. Genes changing at one or both time points are indicated. 648 
c, Scatterplot comparing prion-induced changes in Cx3cr1
+
 cells at the pre-terminal (24 wpi) and 649 
terminal time points. Genes changing at one or both time points are indicated. d, Boxplots displaying 650 
translational changes of neurotoxic (A1 signature) and neuroprotective (A2 signature) genes in 651 
GFAP
+
 cells during prion disease (PrD) progression. e, Boxplots displaying translational changes of 652 
disease-associated microglia (DAM) and homeostatic microglia genes in Cx3cr1
+
 cells during PrD 653 
progression.  654 
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 655 
Figure 5: Different cell types display distinct prion disease related changes. a, Hierarchical 656 
clustering of control and PrD samples at the terminal stage based on Euclidean distances. Heatmaps 657 
depicting the sample distance at each time point based on rlog transformed RPF counts per gene 658 
show a clustering of samples according to treatment and Cre driver (~ cell type). b, Principal 659 
component analysis of control (ctrl) and prion disease (PrD) samples at the terminal stage based on 660 
rlog transformed RPF counts per gene revealing a separation according to Cre driver (~ cell type). c, 661 
Table showing the number of total and cell-type specific (unique) changes in the different cell types at 662 
the terminal stage. d, Scatterplot comparing prion-induced changes between cortical and 663 
hippocampal CamKIIa
+
 cells at the terminal time point. Genes changing in one or both cell types are 664 
indicated. Genes that change in all cell types are shown in green. e, Scatterplot comparing prion-665 
induced changes in GFAP- and Cx3cr1
+
 cells at the terminal time point. Genes changing in one or 666 
both cell types are indicated. Genes that change in all cell types are shown in green. f, Table 667 
displaying top enriched GO terms among genes changing only in GFAP
+
 cells, only in Cx3cr1
+
 cells or 668 
in both glia cell types.  669 
 670 
Figure 6: Cell-type specific ribosome profiling identifies novel prion disease induced changes. 671 
a, Table displaying the number of changes in the different cell types at the terminal stage and how 672 
many of them are preferentially translated genes (PTGs). Shown are numbers of genes that change 673 
either in the ribosome profiling (RP) or the RNAseq or in both datasets. d, Boxplots displaying 674 
terminal RNA expression changes in the hippocampus of all expressed genes and PTGs. c, 675 
Scatterplot comparing prion-induced RNA expression changes in the hippocampus and translational 676 
changes in GFAP
+
 cells. GFAP PTGs and genes that change only in the RP but not the RNAseq 677 
dataset are indicated. d, Scatterplot comparing prion-induced RNA expression changes in the 678 
hippocampus and translational changes in Cx3cr1
+
 cells. Cx3cr1 PTGs and genes that change only in 679 
the RP but not the RNAseq dataset are indicated. e, Bars represent the translation (log2 average of 680 
normalized counts per gene; DESeq2 output) and translational change (log2FC; DESeq2 output) in 681 
the different cell types. Shown are genes that are enriched in astrocytes (Glul and Gfap) and microglia 682 
(Aif1 encoding for IBA1, and Mmp9). Significant changes (Benjamini Hochberg adjusted p value < 683 
0.05; derived from DESeq2 analyses) are marked with an asterisk. f, Western blot and its 684 
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quantification showing protein levels of astrocyte (GLUL and GFAP) and microglia (IBA1 and MMP9) 685 
enriched genes in control (ctrl) and terminal prion disease (PrD) samples (*p<0.05; **p<0.01; 686 
***p<0.001; two-tailed t test comparing terminal PrD vs ctrl samples; error bars: standard deviation). 687 
g, Western blot and its quantification showing neuronal protein levels (NeuN in cortex and 688 
hippocampus, PV in whole brain) in ctrl and terminal PrD samples (ns = not significant; two-tailed t 689 
test comparing terminal PrD vs ctrl samples; error bars: standard deviation).  690 
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Figure Supplement Legends 691 
 692 
Figure 1-figure supplement 1: Generation of mice that express GFP-tagged ribosomes in prion 693 
disease relevant cells. a, Brain sections of control (ctrl) and terminally prion-diseased (PrD) 694 
CamKIIa/Rpl10a:GFP mice were stained for GFP and CamKIIa or NeuN. A subset of NeuN
+
 cells and 695 
all CamKIIa
+
 cells showed Rpl10a:GFP expression in the cortex. No GFP signal was detectable in 696 
Rpl10a:GFP mice (not bred with a Cre expressing strain). b-c, Brain sections of ctrl and PrD 697 
PV/Rpl10a:GFP mice were stained for GFP and PV or NeuN. Cells that were NeuN-negative and PV
+
 698 
showed Rpl10a:GFP expression in the hippocampus (b) and cortex (c). No GFP signal was 699 
detectable in Rpl10a:GFP mice not bred with a Cre expressing strain (PV expression in these mice 700 
was not assessed). d, Brain sections of ctrl and PrD mice expressing Rpl10a:GFP in GFAP
+
 cells 701 
were stained for GFP and GFAP. e, Brain sections of terminally diseased and control mice expressing 702 
Rpl10a:GFP in Cx3cr1
+
 cells were stained for GFP and IBA1. 703 
 704 
Figure 2-figure supplement 1: Analysis of different CNS cells via cell-type specific ribosome 705 
profiling. a, Beeswarm plots displaying million unique reads. Samples are grouped according to 706 
analyzed regions and Cre driver. Only Cre
+
 samples with at least one million unique reads (indicated 707 
by a dashed pink line) were analyzed. One Cre
+
 samples did not pass quality control and was 708 
therefore excluded (encircled in pink). Terminal PrD samples are colored in green. b, Beeswarm plots 709 
displaying the % of reads mapping to ribosomal RNA (rRNA). Samples are grouped according to 710 
analyzed regions and Cre drivers. One Cre
+
 samples did not pass quality control (> one million unique 711 
reads and > 70% of reads mapping to the coding sequence) and was therefore excluded (encircled in 712 
pink). Terminal PrD samples are colored in green. c, Density plots displaying the ribosome protected 713 
fragments (RPF) coverage relative to the translational start (left) and stop (right). RPF counts were 714 
normalized for transcript abundance and the number of transcripts represented at each position. 715 
Shown are representative samples of the different cell types and a Cre-negative sample as well the 716 
excluded Cre
+
 sample. 717 
 718 
Figure 3-figure supplement 1: Marker genes are highly translated in the corresponding cell 719 
type.  Boxplots displaying the translation of marker genes for excitatory neurons 720 
 29 
(L23/4/5_1/5_2/5_3/6), inhibitory neurons (Cck/Npy/Pv/Sst/Vip) and other cell types (Ref) in the 721 
indicated cell type. Boxes containing genes expected to be highly translated are shaded in a darker 722 
tone. 723 
 724 
Figure 3-figure supplement 2: Identification of differentially translated transcripts in different 725 
cell types.  MA plots showing the log2FC in translation between indicated cell types over the mean of 726 
normalized RPFs per gene. Genes that are differentially translated (FDR < 0.05) are colored in pink 727 
and the corresponding numbers are indicated.  728 
 729 
Figure 3-figure supplement 3: Comparison of cell-type specific expression and translation. a, 730 
Cross-correlation plot comparing ribosome profiling (RP; samples #1-5) and ribotag (RT; samples #6-731 
14) data. Pearson correlation coefficients are indicated. RP and RT samples generated from the 732 
same cell type showed the highest correlation and the comparisons are highlighted in the 733 
corresponding color. b, Boxplots displaying the expression (according to RT data) of preferentially 734 
translated genes (PTGs). PTGs showed the highest expression in the corresponding RT datasets. 735 
 736 
Figure 4-figure supplement 1: Principal component analysis of control and prion disease 737 
samples. Principal component analysis of control (ctrl) and prion disease (PrD) samples at different 738 
time points during disease progression. The principal components 1 and 2 are plotted on the x and y 739 
axes, respectively. The % of variance explained by these principal components is indicated. Ctrl and 740 
PrD samples showed a clear separation only at the terminal stage, most prominently in GFAP and 741 
Cx3cr1
+
 cells.  742 
 743 
Figure 4-figure supplement 2: Identification of differentially translated transcripts in different 744 
cell types.  MA plots showing the log2FC in translation between prion disease (PrD) vs control (ctrl) 745 
samples over the mean of normalized RPFs per gene. Genes that are differentially translated (FDR < 746 
0.05) are colored in pink and the corresponding numbers are indicated.  747 
 748 
Figure 4-figure supplement 3: Comparison of prion-induced changes during disease 749 
progression. a-c, Scatterplots comparing prion-induced changes at the pre-terminal (24 weeks post 750 
 30 
inoculation (wpi)) and terminal time points in CamKIIa cortical (a), and hippocampal (b) neurons and 751 
in PV neurons (c). Genes changing at one or both time points are indicated.  752 
 753 
Figure 5-figure supplement 1: Identification of common and cell type-specific translational 754 
changes. a, Cross-correlation plot comparing prion-induced translational changes in different cell 755 
types. Pearson correlation coefficients are indicated. Genes that change in all five datasets are 756 
colored in grey. b, Bars represent the translational change and the translation in the different cell 757 
types. Shown are genes that change in all five datasets. c, Comparison of prion-induced translational 758 
changes in Cx3cr1
+
 cells vs the enrichment in the indicated cell type over Cx3cr1
+
 cells. Genes 759 
changing specifically in Cx3cr1
+
 cells or in both analyzed glia cell types are indicated. Genes that 760 
specifically decreased in Cx3cr1
+
 cells show an enrichment in neuronal cell types over Cx3cr1
+
 cells. 761 
d, Comparison of prion-induced translational changes in GFAP
+
 cells vs the enrichment in the 762 
indicated cell type over GFAP
+
 cells. Genes changing specifically in GFAP
+
 cells or in both analyzed 763 
glia cell types are indicated. GFAP-specific changes are not enriched in any of the analyzed cell 764 
types.  765 
 766 
Figure 6-figure supplement 1: Comparison of prion-induced changes in RNA expression and 767 
translation. a, Comparison between prion-induced cell-type specific translational changes and RNA 768 
expression changes in the hippocampus at 8 weeks post inoculation (wpi). Pearson correlation 769 
coefficients are indicated. b, Comparison between prion-induced cell-type specific translational 770 
changes and RNA expression changes in the hippocampus at the terminal stage. Pearson correlation 771 
coefficients are indicated. Genes that change in either expression (n = 1451; grey circles) or in 772 
translation (colored circles) or in both datasets (colored stars, the corresponding numbers are 773 
displayed) are indicated. 774 
 775 
Figure 6-figure supplement 2: Comparison of GFP expression. a, Western blot showing protein 776 
levels of Calnexin, used for the quantification in Figure 6. b, Western blot and its quantification 777 
showing protein levels in control (ctrl) and terminal prion disease (PrD) GFAP Cre/Rpl10a mice 778 
(*p<0.05; ns = not significant; two-tailed t test comparing terminal PrD vs ctrl samples; error bars: 779 
standard deviation). c, Western blot and its quantification showing protein levels in ctrl and terminal 780 
 31 
PrD Cx3cr1 Cre/Rpl10a mice (*p<0.05; **p<0.01; two-tailed t test comparing terminal PrD vs ctrl 781 
samples; error bars: standard deviation). 782 
 783 
  784 
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Supplementary Table Legends 785 
 786 
Supplementary File 1: Sample Summary. Shown are sample information (sample name, analyzed 787 
region, gender, treatment, time point, Cre driver, and multiplex index), number of unique reads, and 788 
number and percentage of rRNA reads, aligned reads and aligned reads mapping to the coding 789 
sequence (CDS).  790 
 791 
Supplementary File 2: Identification of preferentially translated genes. Table displaying 792 
Ensemble GeneID, MGI Symbol, the individual and average translation (rlog transformed RPF counts 793 
per gene) and difference analysis between all cell types including mean of normalized RPFs per gene 794 
(baseMean), log2FC, pvalue and Benjamini-Hochberg adjusted p values (padj). The last column 795 
specifies preferentially translated genes (PTG), which are differentially translated (|log2FC| > 2 and 796 
padj < 0.05) between one cell type versus all others.  797 
 798 
Supplementary File 3: Comparison of cell-type specific translation and expression. Table 799 
including Ensemble GeneID, MGI Symbol, coding sequence (CDS) length, the individual and average 800 
translation (log2 transformed fpkm values) assessed by ribosome profiling (RP) and the average 801 
expression (log2 transformed fpkm values) assessed by ribotag (RT) in the indicated cell types. 802 
Counts per gene were normalized for sequencing depth and either CDS length (RP) or transcript 803 
length (RT). Additional columns specify if a gene is preferentially translated according to our dataset 804 
(column PTG), if it is one of the top 100 enriched genes according to Zhang et al., 2014 (column 805 
Zhang) or if it was identified to be a marker gene according to Hrvatin et al., 2018 (column Hrvatin).  806 
 807 
Supplementary File 4: Translational changes in CamKIIa cortical neurons during prion disease 808 
progression. Table displaying Ensemble GeneID, MGI Symbol, the individual and average 809 
translation (rlog transformed RPF counts per gene) and difference analysis between prion disease 810 
(PrD) vs control (ctrl) samples through disease progression in CamKIIa cortical neurons, including 811 
mean of normalized RPFs per gene (baseMean), log2FC, pvalue and Benjamini-Hochberg adjusted p 812 
values (padj).   813 
 814 
 33 
Supplementary File 5: Translational changes in CamKIIa hippocampal neurons during prion 815 
disease progression. Table displaying Ensemble GeneID, MGI Symbol, the individual and average 816 
translation (rlog transformed RPF counts per gene) and difference analysis between prion disease 817 
(PrD) vs control (ctrl) samples through disease progression in CamKIIa hippocampal neurons, 818 
including mean of normalized RPFs per gene (baseMean), log2FC, pvalue and Benjamini-Hochberg 819 
adjusted p values (padj).   820 
 821 
Supplementary File 6: Translational changes in PV neurons during prion disease progression. 822 
Table displaying Ensemble GeneID, MGI Symbol, the individual and average translation (rlog 823 
transformed RPF counts per gene) and difference analysis between prion disease (PrD) vs control 824 
(ctrl) samples through disease progression in PV neurons, including mean of normalized RPFs per 825 
gene (baseMean), log2FC, pvalue and Benjamini-Hochberg adjusted p values (padj).   826 
 827 
Supplementary File 7: Translational changes in GFAP
+
 cells during prion disease progression. 828 
Table displaying Ensemble GeneID, MGI Symbol, the individual and average translation (rlog 829 
transformed RPF counts per gene) and difference analysis between prion disease (PrD) vs control 830 
(ctrl) samples through disease progression in GFAP
+
 cells, including mean of normalized RPFs per 831 
gene (baseMean), log2FC, pvalue and Benjamini-Hochberg adjusted p values (padj). Genes 832 
associated with an A1 or an A2 signature are indicated in the last column. 833 
 834 
Supplementary File 8: Translational changes in Cx3cr1
+
 cells during prion disease 835 
progression. Table displaying Ensemble GeneID, MGI Symbol, the individual and average 836 
translation (rlog transformed RPF counts per gene) and difference analysis between prion disease 837 
(PrD) vs control (ctrl) samples through disease progression in Cx3cr1
+
 cells, including mean of 838 
normalized RPFs per gene (baseMean), log2FC, pvalue and Benjamini-Hochberg adjusted p values 839 
(padj). Genes associated with a homeostatic or disease-associated microglia (DAM) signature are 840 
indicated in the last column. 841 
 842 
Supplementary File 9: Summary table of all terminal changes. Table showing Ensemble GeneID, 843 
MGI Symbol, information of genes being preferentially translated (column PTG), and difference 844 
 34 
analysis between prion disease (PrD) vs control (ctrl) samples of cell-type specific translation, and 845 
hippocampal RNA expression changes at the terminal stage intraperitoneally (ip) inoculated mice, 846 
including mean of normalized RPFs per gene (baseMean) for translation, and log2FC and Benjamini-847 
Hochberg adjusted p values (padj) of translational and RNA expression changes. Additional columns 848 
specify if a gene is significantly (|log2FC| > 1 and FDR < 0.05) increasing or decreasing in a dataset 849 
and if decreasing Cx3Cr1-genes are neuronal enriched. 850 
 851 
Supplementary File 10: Gene Ontology analysis of terms related to biological processes. 852 
Genes decreasing and increasing in astrocytes, microglia and in both cell types were compared to 853 
respectively expressed genes.  854 
 855 
Supplementary File 11: Comparison of prion induced expression and cell-type specific 856 
translational changes at the terminal stage. Table showing Ensemble GeneID, MGI Symbol, 857 
information of genes being preferentially translated (column PTG), and difference analysis between 858 
prion disease (PrD) vs control (ctrl) samples of cell-type specific translation at the terminal stage, and 859 
hippocampal RNA expression changes at 8 weeks post inoculation (wpi), and the terminal stage of 860 
intraperitoneally (ip) inoculated mice, including mean of normalized RPFs per gene (baseMean), 861 
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